{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:14Z","timestamp":1761807434901},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11926-008-0019-4","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T22:01:01Z","timestamp":1209938461000},"page":"102-109","source":"Crossref","is-referenced-by-count":17,"title":["Drug-induced osteoporosis: Beyond glucocorticoids"],"prefix":"10.1007","volume":"10","author":[{"given":"Karine","family":"Briot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,4]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D. Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656\u20133661.","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"H.W. Daniell","year":"2000","unstructured":"Daniell HW, Tam HW: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181\u2013186.","journal-title":"J Urol"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"152","author":"V.B. Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 152:154\u2013164.","journal-title":"N Engl J Med"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"T.H. Diamond","year":"2004","unstructured":"Diamond TH, Hiagno CS, Smith MR, et al.: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:892\u2013899.","journal-title":"Cancer"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"M.D. Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonado-tropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038\u20131042.","journal-title":"J Clin Oncol"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/humrep\/deh250","volume":"19","author":"H. Fernandez","year":"2004","unstructured":"Fernandez H, Lucas C, Hedon B, et al.: One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double blind trial. Human Reprod 2004, 19:1465\u20131471.","journal-title":"Human Reprod"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A. Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, et al.; the ATAC Trialists\u2019 Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 2005, 365:60\u201362.","journal-title":"Lancet"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"P.E. Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Robert NJ, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793\u20131802.","journal-title":"N Engl J Med"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"R.C. Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081\u20131092.","journal-title":"N Engl J Med"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"R.E. Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women in early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol 2007, 8:119\u2013127.","journal-title":"Lancet Oncol"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A. Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829\u2013836.","journal-title":"J Clin Oncol"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0404.2005.00474.x","volume":"112","author":"P. Vestergaard","year":"2005","unstructured":"Vestergaard P: Epilepsy, osteoporosis and fracture risk\u2014a meta-analysis. Acta Neurol Scand 2005, 112:277\u2013286.","journal-title":"Acta Neurol Scand"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.nutr.22.120501.150216","volume":"22","author":"J.L. Omdahl","year":"2002","unstructured":"Omdahl JL, Morris HA, May BK: Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annual Rev Nutr 2002, 22:139\u2013166.","journal-title":"Annual Rev Nutr"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.57.3.445","volume":"57","author":"Y. Sato","year":"2001","unstructured":"Sato Y, Kondo I, Ishida S, et al.: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445\u2013449.","journal-title":"Neurology"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1528-1157.2002.15801.x","volume":"43","author":"H.B. Persson","year":"2002","unstructured":"Persson HB, Alberts KA, Farahmand BY, Tomson T: Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002, 43:768\u2013772.","journal-title":"Epilepsia"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0404.1999.tb00675.x","volume":"99","author":"P. Vestergaard","year":"1999","unstructured":"Vestergaard P, Tigaran S, Rejnmark L, et al.: Fracture risk is increased in epilepsy. Acta Neurol Scand 1999, 99:269\u2013275.","journal-title":"Acta Neurol Scand"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.0013-9580.2004.18804.x","volume":"45","author":"P. Vestergaard","year":"2004","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330\u20131337.","journal-title":"Epilepsia"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archneur.58.9.1369","volume":"58","author":"C. Valmadrid","year":"2001","unstructured":"Valmadrid C, Voorhees C, Litt B, Schnever CR: Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001, 58:1369\u20131374.","journal-title":"Arch Neurol"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archinte.159.5.484","volume":"159","author":"M.A. Whooley","year":"1999","unstructured":"Whooley MA, Kip KE, Cauley JA, et al.: Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:484\u2013490.","journal-title":"Arch Intern Med"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.psy.0000132873.50734.7d","volume":"66","author":"M.E. Mussolino","year":"2004","unstructured":"Mussolino ME, Jonas BS, Looker AC: Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med 2004, 66:533\u2013537.","journal-title":"Psychosom Med"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/archinte.167.21.2329","volume":"167","author":"F. Eskandari","year":"2007","unstructured":"Eskandari F, Martinez PE, Torvik S, et al.: Low bone mass in premenopausal women with depression Arch Intern Med 2007, 167:2329\u20132336.","journal-title":"Arch Intern Med"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/aje\/kwg114","volume":"158","author":"R. Hubbard","year":"2003","unstructured":"Hubbard R, Farrington P, Smith C, et al.: Exposure to tricyclic and selective serotonin uptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003, 158:77\u201384.","journal-title":"Am J Epidemiol"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","volume":"17","author":"P. Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006, 17:807\u2013816.","journal-title":"Osteoporos Int"},{"key":"19_CR24","first-page":"291","volume":"3","author":"M. Bliziotes","year":"2002","unstructured":"Bliziotes M Gunness M, Eshleman A, Wiren K: The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2002, 3:291\u2013295.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","volume":"167","author":"J.B. Richards","year":"2007","unstructured":"Richards JB, Papaioannou A, Adachi JD, et al.: Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167:188\u2013194.","journal-title":"Arch Intern Med"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinte.167.12.1246","volume":"167","author":"E.M. Haney","year":"2007","unstructured":"Haney EM, Chan BK, Diem SJ, et al.: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167:1246\u20131251.","journal-title":"Arch Intern Med"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archinte.167.12.1240","volume":"167","author":"S.J. Diem","year":"2007","unstructured":"Diem SJ, Blackwell TL, Stone KL, et al.: Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167:1240\u20131245.","journal-title":"Arch Intern Med"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000054586","volume":"72","author":"J.L. Perez-Castrillon","year":"2000","unstructured":"Perez-Castrillon JL, Olmos JM, Gomez JJ, et al.: Expression of opioid eceptors in osteoblast-like MG 63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 2000, 72:187\u2013194.","journal-title":"Neuroendocrinology"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archinte.163.8.949","volume":"163","author":"K.E. Ensrud","year":"2003","unstructured":"Ensrud KE, Blackwell T, Mangione CM, et al.: Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949\u2013957.","journal-title":"Arch Intern Med"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2796.2006.01667.x","volume":"260","author":"P. Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of morphine and opiates. J Intern Med 2006, 260:76\u201387.","journal-title":"J Intern Med"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00006842-199509000-00011","volume":"57","author":"U. Halbreich","year":"1995","unstructured":"Halbreich U, Rojansky N, Palter S, et al.: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995, 57:485\u2013491.","journal-title":"Psychosom Med"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","volume":"25","author":"V. O\u2019Keane","year":"2005","unstructured":"O\u2019Keane V, Meaney AM: Antipsychotics drugs, a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005, 25:26\u201331.","journal-title":"J Clin Psychopharmacol"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/00207450290025833","volume":"112","author":"M. Bilici","year":"2002","unstructured":"Bilici M, Cakirbay H, Guler M, et al.: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002, 112:317\u2013322.","journal-title":"Int J Neurosci"},{"key":"19_CR34","first-page":"3857","volume":"83","author":"T.W. Mak","year":"1998","unstructured":"Mak TW, Shek CC, Chow CC, et al.: Effects of lithium therapy on bone mineral metabolism: a two year prospective longitudinal study. J Clin Endocrinol Metab 1998, 83:3857\u20133859.","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1073\/pnas.0505259102","volume":"102","author":"P. Cl\u00e9ment-Lacroix","year":"2005","unstructured":"Cl\u00e9ment-Lacroix P, Ai M, Morvan F, et al.: Lrp5-independent activation of Wnt signalling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005, 102:17406\u201317411.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1055\/s-2007-978939","volume":"30","author":"O. Cohen","year":"1998","unstructured":"Cohen O, Rais T, Lepkifker E, Vered I: Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Metab Res 1998, 30:954\u2013957.","journal-title":"Horm Metab Res"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bone.2006.12.055","volume":"40","author":"I. Wilting","year":"2007","unstructured":"Wilting I, de Vries F, Thio BM, et al.: Lithium use and the risk of fractures. Bone 2007, 40:1252\u20131258.","journal-title":"Bone"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-004-0258-y","volume":"77","author":"P. Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Reduced relative risk of fracture among users of lithium. Calcif Tissue Int 2005, 77:1\u20138.","journal-title":"Calcif Tissue Int"},{"key":"19_CR39","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jbmr.5650091012","volume":"9","author":"P. Szulc","year":"1994","unstructured":"Szulc P, Arlot M, Chapuy MC, et al.: Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994, 9:1591\u20131595.","journal-title":"J Bone Miner Res"},{"key":"19_CR40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s001980050169","volume":"5","author":"P.J. Caraballo","year":"1999","unstructured":"Caraballo PJ, Gabriel SE, Castro MR, et al.: Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int 1999, 5:441\u2013448.","journal-title":"Osteoporos Int"},{"key":"19_CR41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-128-10-199805150-00006","volume":"128","author":"S.A. Jamal","year":"1998","unstructured":"Jamal SA, Browner WS, Bauer DC, Cummings SR: Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998, 128:829\u2013832.","journal-title":"Ann Intern Med"},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1001\/archinte.159.15.1750","volume":"159","author":"P.J. Caraballo","year":"1999","unstructured":"Caraballo PJ, Heit JA, Atkinson EJ, et al.: Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999, 159:1750\u20131756.","journal-title":"Arch Intern Med"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2006.07.022","volume":"118","author":"L. Renjmark","year":"2007","unstructured":"Renjmark L, Vestergaard P, Mosekilde L: Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 2007, 118:338\u2013344.","journal-title":"Int J Cardiol"},{"key":"19_CR44","first-page":"69","volume":"31","author":"L. Wawrzynska","year":"2001","unstructured":"Wawrzynska L, Przedlacki J, Hajduk B, et al.: Low-molecular-weight heparins, acenocoumarol and bone density. Haemostasis 2001, 31:69\u201370.","journal-title":"Haemostasis"},{"key":"19_CR45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/bjs.4809","volume":"92","author":"A.E. Handschin","year":"2005","unstructured":"Handschin AE, Trentz OA, Hoerstrup SP, et al.: Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005, 92:177\u2013183.","journal-title":"Br J Surg"},{"key":"19_CR46","doi-asserted-by":"crossref","unstructured":"Rajgopal R, Bear M, Butcher MK, Shaughnessy SG: The effects of heparin and low molecular weight heparins on bone. Thromb Res 2007, [Epub ahead of print].","DOI":"10.1016\/j.thromres.2006.10.025"},{"key":"19_CR47","first-page":"4278","volume":"81","author":"B. Uzzan","year":"1996","unstructured":"Uzzan B, Campos J, Cucherat M, et al.: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996, 81:4278\u20134289.","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1530\/eje.0.1300350","volume":"130","author":"J. Faber","year":"1994","unstructured":"Faber J, Galloe AM: Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994, 130:350\u2013356.","journal-title":"Eur J Endocrinol"},{"key":"19_CR49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.7326\/0003-4819-130-9-199905040-00016","volume":"130","author":"S.L. Greenspan","year":"1999","unstructured":"Greenspan SL, Greenspan FS: The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999, 130:750\u2013758.","journal-title":"Ann Intern Med"},{"key":"19_CR50","first-page":"2931","volume":"82","author":"D.C. Bauer","year":"1997","unstructured":"Bauer DC, Nevitt MC, Ettinger B, Stone K: Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997, 82:2931\u20132936.","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0002-9343(93)90307-B","volume":"95","author":"D.S. Ross","year":"1993","unstructured":"Ross DS: Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinically hypothyroidism: a randomized, prospective study. Am J Med 1993, 95:385\u2013388.","journal-title":"Am J Med"},{"key":"19_CR52","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","volume":"145","author":"S.O. Rzonca","year":"2004","unstructured":"Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401\u2013406.","journal-title":"Endocrinology"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s007740300026","volume":"21","author":"S. Watanabe","year":"2003","unstructured":"Watanabe S, Takeuchi Y, Fukumoto S, et al.: Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Res 2003, 21:166\u2013171.","journal-title":"J Bone Miner Res"},{"key":"19_CR54","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","volume":"91","author":"A.V. Schwartz","year":"2006","unstructured":"Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349\u20133354.","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR55","first-page":"551","volume":"334","author":"R. Short","year":"2007","unstructured":"Short R: Fracture risk is a class effect of glitazones. BMJ 2007, 334:551.","journal-title":"BMJ"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/JBMR.051003","volume":"21","author":"L. Rejnmark","year":"2006","unstructured":"Rejnmark L, Vestergaard P, Heickendorff L, et al.: Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 2006, 21:163\u2013170.","journal-title":"J Bone Miner Res"},{"key":"19_CR57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2796.2005.01585.x","volume":"259","author":"L. Rejnmark","year":"2006","unstructured":"Rejnmark L, Vestergaard P, Mosekilde L: Fracture risk in patients treated with loop diuretics. J Inter Med 2006, 259:117\u2013124.","journal-title":"J Inter Med"},{"key":"19_CR58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","volume":"79","author":"P. Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76\u201383.","journal-title":"Calcif Tissue Int"},{"key":"19_CR59","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"Y.N. Yang","year":"2006","unstructured":"Yang YN, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947\u20132953.","journal-title":"JAMA"},{"key":"19_CR60","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2174\/1381612023393369","volume":"8","author":"C. Farina","year":"2002","unstructured":"Farina C, Gagliardi S: Selective inhibition of osteoclast vacuolar H(+)-AtPase. Curr Pharm Des 2002, 8:2033\u20132048.","journal-title":"Curr Pharm Des"},{"key":"19_CR61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1172\/JCI6145","volume":"106","author":"L. Visentin","year":"2000","unstructured":"Visentin L, Dodds RA, Valente M, et al.: A selective inhibitor of the osteoclastic V-H(+)-Atpase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 2000, 106:309\u2013318.","journal-title":"J Clin Invest"},{"key":"19_CR62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","volume":"41","author":"N.J. Minaur","year":"2002","unstructured":"Minaur NJ, Kounali D, Vedi S, et al.: Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 2002, 41:741\u2013749.","journal-title":"Rheumatology"},{"key":"19_CR63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00198-006-0250-7","volume":"18","author":"L. Rejnmark","year":"2007","unstructured":"Rejnmark L, Vesterggard P, Mosekilde L: Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int 2007, 18:409\u2013417.","journal-title":"Osteoporos Int"},{"key":"19_CR64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1210\/en.2002-220513","volume":"144","author":"R.G. Erben","year":"2003","unstructured":"Erben RG, Brunner KS, Breig B, et al.: Skeletal effects of cyclosporin A are gender related in rats. Endocrinology 2003, 144:40\u201349.","journal-title":"Endocrinology"},{"key":"19_CR65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02678145","volume":"68","author":"A. Monegal","year":"2001","unstructured":"Monegal A, Navasa M, Guanabens B, et al.: Bone mass and mineral metabolism in liver transplant treated with FK 506 or cyclosporine A. Calcif Tissue Int 2001, 68:83\u201386.","journal-title":"Calcif Tissue Int"},{"key":"19_CR66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1359\/JBMR.0301246","volume":"19","author":"C. Amiel","year":"2004","unstructured":"Amiel C, Ostertag A, Slama L, et al.: BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004, 19:402\u2013409.","journal-title":"J Bone Miner Res"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-008-0019-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0019-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:49Z","timestamp":1559436589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-008-0019-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11926-008-0019-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}